ScholarGate
المساعد

قارن الطرق

راجع الطرق التي اخترتها جنبًا إلى جنب؛ الصفوف المختلفة مميَّزة.

تحليل المخاطر المتنافسة التكيفي×تصميم التجربة التكيفي×
المجالعلم الأوبئةالبحوث السريرية
العائلةProcess / pipelineProcess / pipeline
سنة النشأة1999 (foundational Fine-Gray model); adaptive extensions 2000s–2010s1990s-2000s
صاحب الطريقةFine & Gray (subdistribution hazard, 1999); adaptive extensions by Beyersmann, Schumacher and colleaguesStephen Pocock, Christopher Jennison, and statistical methodologists; FDA formalized guidance 2019
النوعStatistical survival analysis with adaptive interim monitoringResearch Design
المصدر التأسيسيFine, J. P., & Gray, R. J. (1999). A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association, 94(446), 496–509. DOI ↗Pocock, S. J. (2005). Current issues in the design and interpretation of clinical trials. BMJ, 330(7500), 1118–1121. link ↗
الأسماء البديلةadaptive Fine-Gray analysis, group-sequential competing risks, adaptive subdistribution hazard analysis, competing risks adaptive designadaptive trial, adaptive design, response-adaptive randomization, RAR
ذات صلة21
الملخصAdaptive competing risks analysis combines the Fine-Gray subdistribution hazard framework — which models the cumulative incidence of one cause of failure in the presence of other mutually exclusive causes — with adaptive or group-sequential interim monitoring rules. This allows a clinical trial or observational study to be modified mid-course (e.g., sample size reassessment, early stopping) based on accumulating competing-risk data while maintaining pre-specified type I error control.An adaptive trial design allows pre-specified modifications to the trial based on interim data—such as sample size re-estimation, stopping for futility or efficacy, dropping ineffective arms, or shifting randomization ratios toward better-performing treatments. Developed systematically in the 1990s–2000s by statisticians like Pocock and Jennison, and formalized by the FDA in 2019, adaptive designs accelerate drug development, reduce exposure to ineffective treatments, and improve efficiency without inflating false-positive rates when properly executed.
ScholarGateمجموعة البيانات
  1. v1
  2. 2 المصادر
  3. PUBLISHED
  1. v1
  2. 3 المصادر
  3. PUBLISHED

انتقل إلى البحث تنزيل الشرائح

ScholarGateقارن الطرق: Adaptive Competing Risks Analysis · Adaptive Trial Design. استُرجع بتاريخ 2026-06-17 من https://scholargate.app/ar/compare